Browse Studies — Arctuva

Observational

NearWave Optical Molecular Monitoring for Predicting Complete Pathological Response (pCR) to Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients

The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pa…

Breast CancerHER2-positive Breast CancerTNBC - Triple-Negative Breast Cancer+2 more

Estimated

~$10 – $6,250

Indiana UniversityNCT06744465

Phase 2

A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatme…

HER2-positive Breast Cancer

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT05325632

Phase 2

TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer

The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn wheth…

Invasive Breast CancerInflammatory Breast Cancer Stage IIIHER2-positive Breast Cancer+2 more

Estimated

~$10 – $7,500

Filipa Lynce, MDNCT05795101

Phase 1

Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy

The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhan…

Breast CancerLocally Advanced Breast CancerNeoadjuvant Chemotherapy+3 more

Estimated

~$10 – $7,500

Alison StopeckNCT06220214

Phase 3

A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice …

Metastatic HER2-positive Breast Cancer

Estimated

~$10 – $8,750

Jazz PharmaceuticalsNCT06435429